Close

REGN Financial Facts

Income tax benefit: -101.08M
Loss from operations: 362.8M
See Full Income Statement

Deferred revenue from Sanofi: 529.79M
Accounts payable and accrued expenses: 714.92M
See Full Balance Sheet

Regeneron Pharmaceuticals, Inc. (REGN) Earnings

  |   Expand Research on REGN
Next EPS Date 2/8/24 EPS Growth Rate -14.8%
Average EPS % Beat Rate +11.6% Revenue Growth Rate -4.4%
Average % Move 1-Wk after EPS -0.0% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
2/8/24 Q423 N/A$10.70 N/A N/A$3.26B N/A N/A N/A
11/2/23 Q323 N/A$10.75 N/A N/A$3.23B N/A N/A N/A
8/3/23 Q223 $10.24$9.85 +$0.39$3.16B$3.03B N/A Details
5/4/23 Q123 $10.09$9.56 +$0.53$3.16B$3B N/A Details
2/3/23 Q422 $12.56$10.17 +$2.39$3.41B$3.13B N/A Details
11/3/22 Q322 $11.14$9.82 +$1.32$2.94B$2.94B N/A Details
8/3/22 Q222 $9.77$8.60 +$1.17$2.86B$2.79B N/A Details
5/4/22 Q122 $11.49$10.04 +$1.45$2.97B$2.73B N/A Details